Skip to content
Screener

Accrued Expenses at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$5.47M-90.8%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$3.22M-8.7%
TRV
Trevi Therapeutics, Inc.TRVI
$4.58M-11.4%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$26.2M-16.8%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.54B+63.2%
Enterprise value$4.87B+84.8%
P/E18.1×-7.7×
P/S3.5×+1.1×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemMarch 31, 2026December 31, 2025
Accounts payable$35$48
Accrued employee-related obligations42103
Accrued indirect tax and government fees520
Accruals for third-party services9276
Accrued other expenses43
Total accounts payable and accrued expenses$178$250

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s accrued expenses?
Indivior Pharmaceuticals, Inc. (INDV) reported accrued expenses of $42M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
Indivior Pharmaceuticals, Inc.'s accrued expenses decreased by 6.7% year-over-year, from $45M to $42M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s accrued expenses?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s accrued expenses has grown at a 60.5% compound annual growth rate (CAGR), from $40M to $103M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Indivior Pharmaceuticals, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude